Where Apellis Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Apellis Pharmaceuticals (NASDAQ:APLS) has received mostly bullish ratings from 21 analysts over the last quarter, with an average price target of $68.38, indicating a potential upside from the current price of $40.04. However, this average has decreased by 27.91% from the previous average price target of $94.85.
August 24, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apellis Pharmaceuticals has received mostly bullish ratings from analysts, indicating a potential upside. However, the decrease in the average price target could impact investor sentiment.
The bullish ratings from analysts indicate a positive outlook for Apellis Pharmaceuticals, which could drive the stock price up in the short term. However, the decrease in the average price target could indicate a less optimistic outlook, which could temper the potential increase in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100